After a touch-and-go review from FDA staff, Takeda's inflammatory bowel disease drug had an easier time convincing an agency advisory panel of its safety and efficacy. But while an FDA committee took little issue with vedolizumab's risk profile,...
Takeda Pharmaceutical Company Limited (TSE:4502) today announced final
Phase 1 and preliminary Phase 2 results of a study combining oral
investigational MLN9708 administered twice a week with lenalidomide and
Genetics, Inc. (Nasdaq: SGEN) and Takeda
Pharmaceutical Company Limited (TSE:4502) today announced updated
overall survival data from two ADCETRIS (brentuximab vedotin) pivotal
Phase 2 clinical trials in...
Millennium: The Takeda Oncology Company with its parent company, Takeda
Pharmaceutical Company Limited (TSE:4502), today announced results from
a retrospective, subgroup analysis of the Phase 3 VISTA study that
showed a higher...
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Takeda
Pharmaceutical Company Limited (Takeda) today announced the signing
earlier this year of an agreement in which Teva licensed to Takeda the
right to commercialize...
Japanese drugmaker Takeda Pharmaceuticals saw an era end last year when generic versions of its top seller, diabetes drug Actos, hit the market. Now it is trying to usher in a bold new era by giving a non-Japanese executive a shot at being CEO at...
November 30, 2013 1:53 PM
TOKYO (AFP) - Japan's top drugmaker said Saturday it had picked a GlaxoSmithKline executive as its next president in a rare example of overseas head-hunting by a major Japanese firm.
Oops! Unable to complete your request. Please refresh your browser.